Mark Stenhouse - Dec 9, 2022 Form 4 Insider Report for Prometheus Biosciences, Inc. (RXDX)

Role: Chief Operating Officer
Signature: /s/ Timothy K. Andrews, attorney-in-fact for Mark Stenhouse
Stock symbol: RXDX
Transactions as of: Dec 9, 2022
Transactions value $: $0
Form type: 4
Date filed: 12/13/2022, 07:38 PM
Previous filing: May 27, 2022
Next filing: May 30, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXDX	Common Stock	Award	$0	+9.81K	+58.99%	$0.00	26.4K	Dec 9, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXDX	Stock Option (Right to Buy)	Award	$0	+34.1K		$0.00	34.1K	Dec 9, 2022	Common Stock	34.1K	$110.20	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Award of restricted stock units ("RSUs") granted under the Issuer's 2021 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award will vest and settle with respect to twenty-five percent (25%) of the total number of RSUs on December 9, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service with the Issuer through each vest date.
F2	Includes a total of 2,631 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
F3	25% of the shares subject to the option will vest on December 9, 2023, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.